Activating NRAS mutations are found in 15% to 20% of melanomas. Immune therapies have become a mainstay in advanced melanoma treatment. We sought to evaluate whether tumor genotype (e.g., NRAS mutations) correlates with benefit from immune therapy in melanoma. We identified 229 patients with melanoma treated with immune therapies [IL2, ipilimumab, or anti-programmed cell death-1/ligand-1 (PD-1/PD-L1)] at three centers and compared clinical outcomes following immune therapy for patients with or without NRAS mutations. Of the 229 patients with melanoma, 60 had NRAS mutation, 53 had BRAF mutation, and 116 had NRAS/BRAF wild type. The NRAS-mutant cohort had superior or a trend to superior outcomes compared with the other cohorts in terms of response to first-line immune therapy (28% vs. 16%, P = 0.04), response to any line of immune therapy (32% vs. 20%, P = 0.07), clinical benefit (response + stable disease lasting ≥24 weeks; 50% vs. 31%, P < 0.01), and progression-free survival (median, 4.1 vs. 2.9 months, P = 0.09). Benefit from anti-PD-1/PD-L1 was particularly marked in the NRAS cohort (clinical benefit rate 73% vs. 35%). In an independent group of patient samples, NRAS-mutant melanoma had higher PD-L1 expression (although not statistically significant) compared with other genotypes (8/12 vs. 9/20 samples with ≥1% expression; 6/12 vs. 6/20 samples with ≥5% expression), suggesting a potential mechanism for the clinical results. This retrospective study suggests that NRAS mutations in advanced melanoma correlate with increased benefit from immune-based therapies compared with other genetic subtypes. If confirmed by prospective studies, this may be explained in part by high rates of PD-L1 expression. Cancer Immunol Res; 3(3); 288-95. ©2015 AACR.
©2015 American Association for Cancer Research.
03/2015; 3(3):288-95. DOI:10.1158/2326-6066.CIR-14-0207
Cancer Research 10/2014; 74(19 Supplement):2942-2942. DOI:10.1158/1538-7445.AM2014-2942 · 9.28 Impact Factor
International Journal of Radiation OncologyBiologyPhysics 11/2012; 84(3):S497. DOI:10.1016/j.ijrobp.2012.07.1322 · 4.18 Impact Factor
Journal of Clinical Oncology 11/2011; 29(33):e809-11. DOI:10.1200/JCO.2011.36.8829 · 17.88 Impact Factor
Fuel and Energy Abstracts 10/2011; 81(2). DOI:10.1016/j.ijrobp.2011.06.1032
European Journal of Cancer 09/2011; 47. DOI:10.1016/S0959-8049(11)72539-4 · 4.82 Impact Factor